Figure 2.

CaMK2A phosphorylation at T286 is reduced in more advanced stages of GBM tumors. (A) Immunohistochemistry (IHC) based comparative and quantitative survey of the non-phosphorylated CaMK2A and its phosphorylation at T286 was performed using glioblastoma patient tissue array with 63 samples from WHO Grade IV (including four pediatric samples, Supplementary Figure S4), three samples from Grade III, four samples from Grade II and six normal controls. The identities of representative samples from each tumor grade as mentioned in the tissue array are specified. (B) Data shows that significantly higher levels of non-phosphorylated CaMK2A protein levels were associated with increase in GBM grade but (C) reverse trend was noticed for the proportion of CaMK2A phosphorylation at T286, which was determined by normalizing the levels of phospho-T286 to non phosphorylated CaMK2A. This suggests that phosphorylation of CaMK2A was tightly regulated in progressive GBM tumor grades and was crucially kept at lower levels. It is to be noted that normal brain samples expressed very high levels of phospho CaMK2A T286. ***p < 0.001. Error bar = SD.